Abstract | BACKGROUND: METHODS: Randomised, placebo-controlled, 5-period crossover study. Patients with persistent asthma (18-75 years, FEV(1) 50-85% predicted, ≥12% and 200 mL FEV(1) reversibility) receiving ICS were randomised to double-blind single dose indacaterol 150, 300, or 600 μg or placebo, with open-label salmeterol 50 μg twice-daily for one day in the 5(th) period. Primary endpoint was FEV(1)AUC(22-24h). RESULTS: Of 41 randomised patients (48.8% male; mean age: 47.8 years), 39 completed. All indacaterol doses showed significantly higher FEV(1)AUC(22-24h) than placebo (P<0.001), with treatment-placebo differences of 180, 220, and 260 mL for indacaterol 150, 300, and 600 μg, respectively ( salmeterol-placebo difference 170 mL; P < 0.001). For individual time-point FEV(1), all indacaterol doses were superior to placebo from 5 min to 24h post-dose (P < 0.001). Compared with salmeterol, all indacaterol doses were superior from 5 to 30 min (P < 0.05); in addition indacaterol 300 μg and 600 μg were superior at a number of subsequent time points. Changes in safety parameters with indacaterol were similar to placebo. All indacaterol doses were well tolerated. CONCLUSION: Single dose indacaterol provided sustained 24-h bronchodilation with a faster onset of action than salmeterol and a good overall safety and tolerability profile in Japanese patients with asthma. These results are consistent with data from Caucasian populations.
|
Authors | Naruhiko Sugihara, Shigeto Kanada, Michiko Haida, Masakazu Ichinose, Mitsuru Adachi, Motoi Hosoe, Charlotte Emery, Mark Higgins, Benjamin Kramer |
Journal | Respiratory medicine
(Respir Med)
Vol. 104
Issue 11
Pg. 1629-37
(Nov 2010)
ISSN: 1532-3064 [Electronic] England |
PMID | 20619623
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 Elsevier Ltd. All rights reserved. |
Chemical References |
- Bronchodilator Agents
- Indans
- Placebos
- Quinolones
- Salmeterol Xinafoate
- indacaterol
- Albuterol
|
Topics |
- Administration, Inhalation
- Adolescent
- Adult
- Aged
- Albuterol
(administration & dosage, analogs & derivatives)
- Asthma
(drug therapy, physiopathology)
- Bronchodilator Agents
(administration & dosage)
- Cross-Over Studies
- Double-Blind Method
- Female
- Forced Expiratory Volume
(physiology)
- Humans
- Indans
(administration & dosage)
- Japan
- Male
- Middle Aged
- Placebos
- Practice Guidelines as Topic
- Quinolones
(administration & dosage)
- Respiratory Function Tests
- Salmeterol Xinafoate
- Treatment Outcome
- Young Adult
|